|Accueil | Aperçu | Revues | Soumettre | Nous Contacter | English|
We determined whether hyperglycaemia stimulates human beta cell replication in vivo in an islet transplant model
Human islets were transplanted into streptozotocin-induced diabetic NOD–severe combined immunodeficiency mice. Blood glucose was measured serially during a 2 week graft revascularisation period. Engrafted mice were then catheterised in the femoral artery and vein, and infused intravenously with BrdU for 4 days to label replicating beta cells. Mice with restored normoglycaemia were co-infused with either 0.9% (wt/vol.) saline or 50% (wt/vol.) glucose to generate glycaemic differences among grafts from the same donors. During infusions, blood glucose was measured daily. After infusion, human beta cell replication and apoptosis were measured in graft sections using immunofluorescence for insulin, and BrdU or TUNEL.
Human islet grafts corrected diabetes in the majority of cases. Among grafts from the same donor, human beta cell proliferation doubled in those exposed to higher glucose relative to lower glucose. Across the entire cohort of grafts, higher blood glucose was strongly correlated with increased beta cell replication. Beta cell replication rates were unrelated to circulating human insulin levels or donor age, but tended to correlate with donor BMI. Beta cell TUNEL reactivity was not measurably increased in grafts exposed to elevated blood glucose.
Glucose is a mitogenic stimulus for transplanted human beta cells in vivo. Investigating the underlying pathways may point to mechanisms capable of expanding human beta cell mass in vivo.
Expansion of human beta cells through replication is one of the principal goals of current diabetes research. However, techniques to expand human beta cells lag behind those for rodents. Human islets are different from rodent islets with respect to cellular composition, architecture, toxin susceptibility, replication rates and even fundamental properties such as basement membrane structure and means of glucose transport [1-8]. To this end, translating findings described in rodents to human beta cells is non-trivial and important.
We set out to determine whether elevated glucose stimulates human beta cell replication in vivo. This is a fundamental, unanswered question with direct implications for diabetes care, as the answers may identify pathways leading to new therapeutics and may also help establish optimal glycaemic control in recipients of islet transplants.
Glucose drives rodent beta cell replication in vitro [9-12] and in vivo [13-18]. Teleologically, high glucose levels should direct beta cell expansion, thus increasing insulin secretory capacity. In general, replication in adult human beta cells is infrequent [19-22]. Studies exploring whether hyperglycaemia is associated with increased beta cell replication in the endogenous human pancreas are equivocal. In a large autopsy-based study no increase in beta cell replication was seen in diabetic individuals . A patient with new-onset type 1 diabetes, who required pancreatectomy for an unrelated reason, was reported to have increased beta cell replication . However, in individuals newly diagnosed with diabetes who died from ketoacidosis, beta cell replication was not increased . Patients requiring two sequential pancreatectomy surgery procedures had elevated blood glucose at the time of the second procedure, but no increase in beta cell replication . Therefore, studies of human pancreas tissue do not support the hypothesis that hyperglycaemia increases human beta cell replication, although the many variables attendant to human life, disease and death may mask findings.
Nevertheless, in vitro studies do suggest that glucose stimulates human beta cell replication during short-term exposure. High glucose (33 mmol/l) increased proliferation after 1 to 2 days of culture, but inhibited proliferation and caused cell death after 4 to 10 days of culture [23-25]. Human beta cell replication was higher after 2 days in culture at 5.6 mmol/l glucose than at 2.8 mmol/l . Glucose synergised with lithium chloride to activate human beta cell replication (8 mmol/l vs 5 mmol/l) . Thus, cell culture experiments do suggest that glucose may have mitogenic effects on human beta cells.
Transplantation of human islets into immune-compromised mice is a useful technique to study human beta cells in an in vivo environment [28, 29]. Engrafted human islets exposed for 2 weeks to either severe hyperglycaemia (24 mmol/l) or normoglycaemia (4 mmol/l) showed no difference in beta cell replication . On the other hand, human islets transplanted into obese hyperglycaemic (9.0 mmol/l vs 6.4 mmol/l) ob/ob mice had a doubled rate of beta cell proliferation . To date, no study has effectively isolated glucose as a variable for determining whether hyperglycaemia in a physiologically relevant range alters human beta cell replication in vivo.
We have previously shown that hyperglycaemia induced by intravenous infusion of glucose increases beta cell replication in the mouse pancreas . To explore the impact of glucose on human beta cell replication in vivo, we have now applied the infusion model to mice transplanted with human islets. This experimental set-up delivers significant advances over previous technologies, including: (1) exposure of engrafted human islets to a controlled physiological range of blood glucose levels, relevant to the normal and prediabetic postprandial state; (2) isolation of glucose as a variable, without confounding effects due to obesity and chronic diabetes; (3) constant delivery of BrdU regardless of glycaemic status; and (4) serial unhandled blood sampling to avoid stress-related variability in glucose measurements. Using this system, we tested whether elevated blood glucose stimulates human beta cell proliferation in vivo.
Islets from 12 non-diabetic human cadaveric donors were obtained from the Islet Cell Resource Center (ICRC; http://icr.coh.org/, accessed 7 September 2010) (Table 1). Donors ranged in age from 27 to 76 years; islets from one 7-year-old donor were initially included in the study, but were subsequently excluded from analyses because of the marked biological differences between juvenile and adult islets . Of the remaining 11 donors, four were female, six male and one unrecorded. BMI ranged from low-normal (19.6 kg/m2) to severely obese (43.8 kg/m2). ICRC-determined islet purity was between 70 and 95%, viability was between 80 and 95%.
All animal handling was in accordance with approved Institutional Animal Care and Use Committee protocols at the University of Pittsburgh; use of human islets was approved by the University of Pittsburgh Institutional Review Board. Human islets were transplanted under the kidney capsule of 2- to 3-month-old, streptozotocin-induced diabetic male NOD–severe combined immunodeficiency (SCID) mice (Jackson laboratory, Bar Harbor, ME, USA) as previously described . Briefly, NOD–SCID mice were rendered diabetic by intraperitoneal injection of 125 mg/kg streptozotocin for two consecutive days. Diabetes was determined by the presence of hyperglycaemia (>16.7 mmol/l), polyuria and weight loss. Random non-fasted blood glucose was measured from tail snip using a portable glucometer. After at least 3 days of hyperglycaemia, mice were transplanted with 2,500 to 4,000 islet equivalents (IEQ) beneath the kidney capsule. IEQ was defined as: 125 μm diameter islet=1 IEQ. The initial two transplants were 4,000 IEQ, but subsequently the number of IEQ transplanted per donor was reduced until it became clear that 2,500 IEQ were sufficient to reverse hyperglycaemia [28, 29]. Recipients receiving >2,500 IEQ were not different from those receiving 2,500 IEQ with respect to blood glucose, plasma insulin, age or BMI. Multiple mice transplanted from the same donor received the same number of IEQ. Blood glucose levels were measured on days 1, 3, 5, 10 and 14 after transplant, before surgical catheterisation and infusion.
Detailed protocols on surgical catheterisation, tether system, housing, catheter maintenance, arterial blood sampling, erythrocyte return and techniques for venous infusion can be found in the online supplement of a previous publication . Transplanted mice with free access to food and water were catheterised 14 days after transplant, in the femoral artery and vein, using a sterile technique. After 3 days recovery, mice were infused for 4 days with 0.9% saline or 50% glucose (both wt/vol.) at 100 μl/h (approximately 2 g kg−1h−1). Mice with elevated blood glucose 14 days after transplant (>11.1 mmol/l; n=5) received saline; mice with blood glucose <11.1 mmol/l received either saline (n=6) or glucose (n=8). Three grafts, all from donor 10, did not have blood glucose measured on day 14 after transplant; all three had hyperglycaemia during the infusion period (14.2, 24.2 and 29.3 mmol/l) and were put in the >11 mmol/l blood glucose group. When several normoglycaemic grafted mice were available from one donor (donors 4, 5, 7 and 9 [Table 1]), one mouse received saline and the other(s) received glucose. Grafts from donors 1, 8 and 10, and one graft from donor 11, had blood glucose >11 mmol/l. Infusates contained 250 μg/ml BrdU, for continuous exposure of 25 μg/h over the 4 days. Morning (postprandial) arterial blood was sampled from the unhandled mice via catheter at 0, 24, 48, 72 and 96 h of infusion. Following infusion, the mice were killed, and pancreases and engrafted kidneys fixed for histological analysis.
Blood glucose was measured using a portable glucometer (Precision QID; Abbot Laboratories, Abbot Park, IL, USA) before and a glucometer (Ascencia Elite XL; Bayer, Tarrytown, NY, USA) after catheterisation. Plasma mouse and human insulin were measured by radioimmunoassay (Millipore/Linco, St Charles, MO, USA); cross-reactivity of the human assay with human proinsulin is <0.2% and with rodent insulin <0.1%. Cross-reactivity of the rodent insulin assay with human insulin is high; mouse insulin values were obtained by subtracting measured human insulin from rodent (total) insulin.
Engrafted kidneys were fixed in Bouin’s solution (Sigma, St Louis, MO, USA) for 4 h at room temperature, dehydrated, embedded in paraffin and sectioned (5 μm). For BrdU/insulin immunofluorescence, sections were rehydrated, incubated in 1 mol/l HCl for 30 min at 37°C, blocked in PBS with 5% vol./vol. goat serum and 1% (wt/vol.) BSA, and exposed overnight to anti-BrdU (1:200; Abcam, Cambridge, MA, USA) and anti-insulin (1:50; Invitrogen, Carlsbad, CA, USA) antibodies at 4°C, followed by exposure to fluorescent secondary antibodies (Alexa 488 and 594 conjugated, 1:200, and Hoechst, 1:1,000; all from Invitrogen). For macrophage marker F4/80–insulin–BrdU–DAPI co-staining, paraffin sections were rehydrated, digested with pepsin (Digest-All; Invitrogen), permeabilised in 0.1% vol./vol. Triton X-100 in PBS, blocked and stained exactly as above using primary antibodies for insulin (1:500; Invitrogen), F4/80 (1:100; Abcam) and BrdU (1:5; Amersham, Piscataway, NJ, USA), and an additional secondary antibody conjugated to Cy5 (1:200; Invitrogen). TUNEL staining was performed using a kit (Dead End kit; Promega, Madison, WI, USA) followed by immunofluorescence staining for insulin and Hoechst as above.
For BrdU and TUNEL quantification, stained sections were imaged using an upright fluorescence microscope (Provis; Olympus, Center Valley, PA, USA) at ×400, blinded and insulin-positive and TUNEL- or BrdU-positive beta cells manually counted. For BrdU, 3,034±246 beta cells were counted per graft; for TUNEL 2,618±317 beta cells were counted per graft. To verify BrdU and insulin colocalisation in the same cell and to determine whether insulin-positive BrdU-positive cells represented macrophages engulfing dying beta cells, confocal microscopy was performed (Fluoview 1000; Olympus) at ×400.
All data are presented as mean±SEM or as individual values. Statistical significance was calculated by Prism 4 (GraphPad Software, La Jolla, CA, USA), using Student’s t tests. One-way ANOVA was used when comparing multiple groups, with Tukey’s Multiple Comparison Test. Two-way ANOVA was used when comparing blood glucose differences over time between infusion groups. Linear regressions were calculated by GraphPad Prism, with reported p values signifying whether the slope of the regression line was significantly different from zero. For all analyses, p<0.05 was considered significant.
The experimental protocol is depicted in Fig. 1. The majority of grafts normalised blood glucose within 2 weeks of transplant (blood glucose <11 mmol/l, n=14) (Fig. 2a). Grafts that failed to normalise blood glucose (blood glucose >11 mmol/l, n=8) (Fig. 2a) were continued through the protocol to obtain data for human beta cells chronically exposed to higher blood glucose levels. Blood glucose values dipped 1 day after transplant, rebounded slightly and then slowly descended to stable levels by 2 weeks after transplant. With one exception, duplicate grafts were similarly effective in normalising blood glucose (Fig. 2b). Successful blood glucose normalisation was not significantly associated with donor age, BMI, sex, islet purity or islet viability (data not shown).
Histological analysis of the endogenous mouse pancreas after death verified mouse beta cell ablation by streptozotocin without re-growth. Only rare, small, abnormal-appearing islets were observed, with few to no beta cells (Fig. 2c). Circulating mouse insulin was undetectable (Fig. 2d).
Blood glucose remained elevated in the >11 mmol/l blood glucose group and remained low in normoglycaemic mice infused with saline (Fig. 3a). Note that samples were morning, postprandial samples. In general, blood glucose values during infusion were slightly lower than pre-infusion, presumably due to differences in sampling method (tail snip vs arterial catheter). Mice infused with glucose showed a significant increase in circulating blood glucose and plasma human insulin during the infusion period (Fig. 3a, b). The range of blood glucose and human insulin levels can be seen in Fig. 3c. Note that all replication analyses (see below) are based on cumulative BrdU exposure during this 4 day infusion period. Examination of circulating human insulin relative to blood glucose showed that most mice clustered in one region, with glucose at 3.0 to 8.0 mmol/l and insulin at 100 to 350 pmol/l (Fig. 3c). Mice that remained hyperglycaemic despite the human islet graft had relatively less circulating human insulin on average than mice infused with glucose (Fig. 3c, d).
BrdU-positive nuclei were easily visualised in non-beta cells in graft sections and were occasionally found in human beta cells. Confocal microscopy confirmed that BrdU-positive nuclei were associated with insulin-positive cytoplasm (Fig. 4a–d). To exclude the possibility that colocalisation of BrdU with insulin represented cells of monocyte lineage that had incorporated BrdU, travelled to the graft and then engulfed insulin-positive material, we co-labelled graft sections with BrdU, insulin and the macrophage marker F4/80. Control liver tissue demonstrated F4/80 staining as expected, without non-specific labelling (Fig. 4e, f). Macrophages were observed in graft sections, most frequently in the kidney tissue near the graft perimeter, and also occasionally within the graft tissue itself (Fig. 4g). Non-specific F4/80 staining was not observed in graft tissue (Fig. 4h). BrdU-positive insulin-positive cells did not co-localise with F4/80 staining (Fig. 4i–k).
Previous studies have shown that 4 day exposure of normal mouse pancreatic beta cells to mild hyperglycaemia induces beta cell replication . To determine whether 4 days of hyperglycaemia stimulated engrafted human beta cell proliferation, we restricted analysis to donor pairs in which: (1) islets from one donor were transplanted into at least two mice; (2) blood glucose was normalised in all recipients; and (3) the resulting mice were infused with either saline or glucose to yield a range of blood glucose environments for a 4 day period. In these mice, beta cell replication among grafts from the same donor was higher in those grafts exposed to higher blood glucose (Fig. 4l). The increase in replication was remarkably consistent among donors. The absolute rate of replication intrinsic to each donor was variable, underscoring the difficult nature of human beta cell research. When the rates were averaged for these four donors, human beta cell replication was doubled in grafts exposed to higher glucose (Fig. 4m).
Analysing replication in the entire cohort of adult grafts showed a dose-dependent increase in human beta cell BrdU incorporation across a wide range of blood glucose (Fig. 5a). The correlation between blood glucose and replication was strongest for grafts exposed to blood glucose <16.7 mmol/l, but was still highly significant when all grafts were included. Circulating blood glucose correlated with increased beta cell replication even when the glucose group (n=8) was analysed independently (p=0.039 for glucose mice; correlation not depicted on plot to aid readability) (Fig. 5a). Two grafts from a 7-year-old donor are shown as a positive control, but were not included in any statistical analyses. Note that the grafts from this juvenile donor also showed increased replication in the graft exposed to higher glucose (Fig. 5a). Grafts exposed to very high blood glucose (>16.7 mmol/l) showed more variability in proliferation; two grafts had high rates, but two others had low rates.
When the cohort was analysed by blood glucose quartile (Fig. 5b), human beta cell replication increased above blood glucose 6.0 mmol/l, reaching significance for the highest glucose quartile relative to the two lowest quartiles.
We also explored whether human beta cell proliferation correlated with circulating plasma human insulin levels. Autocrine and/or paracrine insulin action is a putative mechanism by which glucose might stimulate beta cell mitogenesis . In these grafts, human beta cell replication did not correlate with circulating plasma human insulin (Fig. 5c).
As we obtained blood glucose data from the period after transplant but before catheterisation, we sought to determine whether prolonged hyperglycaemia had an effect on transplanted human beta cell replication. When beta cell replication was compared with blood glucose during the week prior to catheterisation, (second week after transplant), a positive correlation was observed (Fig. 5d). This suggests that at least 2 weeks of hyperglycaemia in this range of blood glucose concentration did not prevent human beta cell proliferation.
Rare TUNEL-positive beta cells were found in human islet grafts; representative images are shown in Fig. 6a–c. In this cohort, high glucose was not associated with increased apoptosis at the end of the experiment (Fig. 6d). When grafts from the same donor were compared with each other, higher blood glucose was not associated with increased or decreased TUNEL-positive beta cells. The percentage of TUNEL-positive beta cells was not related to circulating human insulin, donor age or donor BMI (Fig. 6e and data not shown).
Intriguingly, graft human beta cell replication showed a trend towards a positive correlation with increasing donor BMI (Fig. 7a). When replication was analysed with respect to donor age, however, no age-related decline in replication was found in this cohort (Fig. 7b). Mice engrafted with islets from the oldest donor also had higher blood glucose levels, which perhaps masked an age-related decline in human beta cell proliferation.
We have found that glucose drives human beta cell proliferation in vivo in a transplant setting. Regardless of whether the data were analysed within individual donors exposed to 4 days of higher glucose or across the entire cohort of grafts, higher blood glucose led to increased human beta cell replication. Using this controlled model system, we were able to detect increases in beta cell replication associated with small changes in blood glucose, within or near the normal human postprandial range.
The most important finding of this study is the unequivocal demonstration that human beta cell replication increases, in vivo, in response to a moderate delta in blood glucose. To our knowledge, this represents the first direct evidence that human beta cell replication can be induced through a normal physiological stimulus in a setting where human islets are supporting metabolic requirements. Additional strengths include the novel technique of applying the infusion system to transplanted human islets, and the potentially interesting observation that replication showed a trend towards correlation with donor BMI. Weaknesses stem from the intrinsic variability of cadaveric human islets and the generally low rate of replication in human beta cells. BrdU exposure was continuous for 4 days, so all replication events occurring during this time period, including daughter cells, were captured.
The optimal degree of hyperglycaemia to stimulate human beta cell replication is an important question. Our data suggest that to promote proliferation uniformly across all donors blood glucose elevation should not exceed 16.7 mmol/l. This is in agreement with in vitro data that 33 mmol/l glucose reduced proliferation after 4 to 5 days in culture [23-25] and with in vivo data showing that transplanted human islets exposed to 24 mmol/l glucose for 14 days showed no increase in beta cell replication . Our findings support the notion that glucose played a role in the proliferation increase seen in human islets transplanted into ob/ob mice (blood glucose 9 mmol/l) . These observations raise the interesting possibility that mild hyperglycaemia provides a permissive environment in which other mitogens can induce beta cell replication .
The optimal duration of hyperglycaemia needed to stimulate human beta cell proliferation is unknown. Prolonged hyperglycaemia has been shown to negatively impact rodent and human beta cell function and/or proliferation in a variety of studies [23-25, 34-38]. We found here that higher blood glucose during the period of BrdU exposure correlated with replication. Interestingly, blood glucose during the week before BrdU exposure also significantly correlated with replication. Blood glucose levels during BrdU exposure were strongly correlated with blood glucose levels in the week before BrdU exposure (r2=0.59, p=0.002). Therefore, prolonged mild glucose elevation may not inhibit beta cell replication in vivo. Since replication was not measured during any earlier period, we cannot exclude the possibility that proliferation rates were higher after a shorter exposure to hyperglycaemia. Interestingly, mouse beta cell replication only increased on the last day of a 4 day glucose infusion . This lag between the onset of hyperglycaemia and the onset of proliferation might be exaggerated in human beta cells relative to mouse, given the low basal level of replication seen in human beta cells.
The model system used here is novel and will prove versatile for future studies. Transplanting human islets isolates them from their native donor environment, eliminating confounding issues related to peripheral insulin sensitivity and other tissue interactions with the beta cell. In this way, we were able to restrict human variability to factors intrinsic to the islets themselves. Transplantation allows culture before-hand, which provides an opportunity to pre-treat the islets with chemical modulators and/or for viral delivery of genes. Catheterisation has many benefits: unhandled blood sampling, sampling volumes that allow measurement of insulin and other factors, and co-administration of nutrients and medications. Also, continuous delivery of a constant amount of BrdU offers advantages over drinking water delivery in animal models of diabetes, in which hyperglycaemia-related polydipsia may alter BrdU exposure among study animals.
We found a trend towards correlation between beta cell replication and higher donor BMI. In rodents, genetic- and diet-induced obesity is a strong proliferative signal to beta cells . In humans, autopsy studies have found that beta cell mass is increased in non-diabetic obese individuals; replication in human obesity is controversial [22, 40, 41]. The increased beta cell mass in obese non-diabetic people may be related to greater developmentally acquired beta cell mass, less beta cell death and/or increased beta cell replication. Our finding supports the concept that factors related to higher BMI, yet intrinsic to islets, might stimulate human beta cell replication. Recent work shows that islets from human donors with higher BMI have pro-proliferative changes at the transcriptional level compared with control islets .
Interestingly, in our cohort, donor age was not a determinant of beta cell proliferation among adult donors. However, beta cells from a 7-year-old donor did show markedly increased replication relative to all adult donors, consistent with published findings of high beta cell replication rates in youth . Our cohort had only one donor over the age of 60, so perhaps the spread of ages was not sufficient to detect an impact of age on proliferation. It may be worth noting that the two outlier points in Fig. 5a, with high glucose but very low replication rates, are both from the 76-year-old donor.
Beta cell death was not influenced by hyperglycaemia, donor age or donor BMI. Although there is strong evidence in the literature suggesting that chronic exposure to high glucose results in beta cell death  we did not detect this effect, even though several of the grafts were exposed to high blood glucose for longer than 2 weeks. The measured rates of TUNEL-positive beta cells were extremely low, in many cases undetectable, so potentially a correlation with hyperglycaemia might have been missed. Exposure to high glucose has been shown to increase expression of interleukin 1β which may contribute to inflammation and beta cell death . It is possible that beta cell death occurred at earlier time points.
Many unanswered questions remain. The discovery that glucose acts as a mitogen for transplanted human beta cells in vivo represents an important step towards identifying conditions in which human beta expansion can occur. In the future we plan to investigate which pathways are activated by glucose in human beta cells, which cell cycle molecules contribute to glucose-induced human beta cell replication and what are the optimal dose and duration of glucose exposure to induce human beta cell proliferation. Perhaps these data will provide the basis for a novel approach to human beta cell mass expansion, which may allow us to treat or even prevent, diabetes and its complications.
We gratefully acknowledge access to human islet samples donated by individuals and provided by the Juvenile Diabetes Research Fund (JDRF), and the NIH/NCRR- and NIDDK-supported Islet Cell Resource Centers. This work was supported by JDRF innovative award 5-2008-189 (to L. C. Alonso and A. Garcia-Ocaña) and grants 1-2008-39 and 34-2008-630 (to A. F. Stewart). Support also came from NIH/NIDDK grants K08 DK076562 (to L. C. Alonso), R01 DK077096 (to A. Garcia-Ocaña) and R01 DK55023 (to A. F. Stewart), and NIH/NIDDK Beta Cell Biology Consortium grant U01 DK072473 (to A. F. Stewart) and NIH/NHLBI grant R01 HL063767 (to C. P. O’Donnell). We are especially grateful to R. Vasavada for her thoughtful reflection and comments, and to staff at investigator (L. C. Alonso, A. F. Stewart, A. Vasavada, A. Garcia-Ocana and C. P. O’Donnell) laboratories for their support and input.
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
H. E. Levitt, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
T. J. Cyphert, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
J. L. Pascoe, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
D. A. Hollern, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
N. Abraham, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
R. J. Lundell, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
T. Rosa, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
L. C. Romano, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
B. Zou, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
C. P. O’Donnell, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
A. F. Stewart, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
A. Garcia-Ocaña, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
L. C. Alonso, Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.